XML 62 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Long-Term Investments (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Braingenesis Biotechnology Co., Ltd [Member]    
Ownership percentage 0.17% 0.17%
Accounting treatments Cost Method  
Genepharm Biotech Corporation [Member]    
Ownership percentage 0.70% 0.72%
Accounting treatments Cost Method  
BioHopeKing Corporation [Member]    
Ownership percentage 5.90% 7.13%
Accounting treatments Cost Method  
BioFirst Corporation [Member]    
Ownership percentage 15.99% 15.89%
Accounting treatments Equity Method  
Rgene Corporation [Member]    
Ownership percentage 31.62% 31.61%
Accounting treatments Equity Method